Fulcrum Therapeutics vs Spero Therapeutics
FULC and SPRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FULC and SPRO compare
Fulcrum Therapeutics is the larger company, worth 4.9 times as much as Spero Therapeutics ($288M against $58.2M).
Fulcrum Therapeutics scores higher on the StockData Score (8 against 6 for Spero Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FULC | SPRO |
|---|---|---|
| Size and price | ||
| Market cap | $288M | $58.2M |
| Share price | $3.77 | $1.000 |
| Change, 1 year | −54.9% | −62.4% |
| Change, 5 years | −78.0% | −93.9% |
| Beta (5Y) | 1.56 | 1.12 |
| Employees | 55 | 25 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.4× |
| P/B | 1.0× (better) | 74.6× |
| FCF yield | −22.7% | – |
| Growth | ||
| Revenue growth (TTM) | – | 2.5% |
| Revenue growth, 5Y average | – | 48.2% |
| Profitability | ||
| Operating margin | – | −67.3% |
| Net margin | – | −71.0% |
| Return on equity | −30.5% (better) | −216% |
| Return on invested capital | −41.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 36.19 (better) | 1.92 |
| Altman Z-score | 16.95 (better) | −6.09 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 112% | 36.9% |
| Held by insiders | 34.7% | 24.6% |
| Insider net buying, 12 months | −$57.5M | −$499K (better) |
| Short interest, % of float | 12.9% | 1.8% |
Go deeper
- FULC stock overview
- FULC income statement
- FULC valuation and score
- SPRO stock overview
- SPRO income statement
- SPRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.